Commentary

For most technology and life-science companies, intellectual property is a critical business asset, according to attorney and WTN guest columnist Sverre Roang. He asserts that intellectual property can be worth millions if it's handled the right way; unfortunately, that's a big IF, and entrepreneurs must...

If you thought the rules for romance were involved, wait until you see the rules for courting angel or venture investors. Yes, there are certain rules of the investment game that entrepreneurs must adhere to, according to columnist Paul Jones, president of the Council for...

Maneuvering through the nuances of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs can be daunting and overwhelming. In this WTN guest column, Pat Dillon of the Wisconsin Entrepreneurs Network tries to take some of the mystery out of the...

Should companies mention climate change as a risk consideration? Whether they should or not, organizations are increasingly factoring this into their risk assessment process and disclosures, according to columnist and accounting executive Amy Borun. In this edition of Boardroom Perspectives, Borun said New York State...

Now that they have been busted, what will happen to the clever souls that earned their fortunes by inventing and marketing increasingly complex securities to increasingly clueless customers? In this look at the venture capital fallout from the credit crunch, WTN guest columnist Paul Jones...

Sending bulk e-mails and other messages has been restricted by hidden limits on your account, and this has been going on for several months, observes columnist James Carlini. In this edtion of Carlini's Comments, he puts AT&T on the griddle for establishing a monthly usage...

In Robert Merrill's estimation, accurate software estimates are a myth. Merrill, a columnist and software entrepreneur, advises software intensive businesses to wake up to the reality that estimates may never be good enough. Even the best estimates don't tell us about uncertainties due to team...

How much longer will the Midwest dominate the medical device landscape? That's what Yer Biotech Blues columnist Michael Rosen wonders after a recent trip to Switzerland. While 10 of the top 20 medical device companies have their headquarters in the Midwest, growth in the medical...

For several election cycles, Big Pharma has been delivering the mother's milk of politics, namely money, to the Republican Party, but 2008 is different. In this edition of Biotech Takes, columnist Steve Clark notes the pharmaceutical industry has made a dramatic, not to mention pragmatic...